News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kibow Biotech, Inc. to Present at Biotechnology Industry Organization (BIO) 2009 International Convention: Innovations to Heal, Fuel, and Feed the World


5/14/2009 8:28:06 AM

NEWTOWN SQUARE, Pa., May 14 /PRNewswire/ -- The Philadelphia area-based probiotics firm Kibow Biotech will be one of only three (3) Pennsylvania companies invited to present at the BIO 2009 Company Forum, http://www.convention.bio.org, in Atlanta, GA on Tuesday, May 19. BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 member companies and institutions worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies.

Dr. Natarajan Ranganathan, Interim CEO and Senior VP (R&D) of Kibow Biotech, stated, "It is indeed an honor to be selected to be part of this forward-looking group of biotech leaders. I will be presenting the technology and accomplishments of Kibow Biotech, which include the recent launch of Kibow Biotics(R), a patented and proprietary probiotic formulation in support of renal health. Our veterinary formulation, for dogs and cats with moderate to severe kidney failure, has been successfully sold on the North American market for the past three years." The veterinary product is called Azodyl(TM) and is marketed by Vetoquinol - USA, Fort Worth, Texas.

Kibow Biotics was made available in the US (http://www.kibow.com) and in Canada (http://www.gelda.com) in April 2009. The product is a dietary supplement and not a drug; it is not intended to be used as a drug or as a substitute for any drug application. The Company encourages referrals from healthcare professionals, even though Kibow Biotics is a non-prescription product. Scientifically developed and clinically tested, Kibow Biotics contains three distinct strains of carefully researched and specifically selected beneficial microbes (probiotics) that possess a high affinity for various nitrogenous waste products. When the kidneys are unable to filter toxins normally, the microbes metabolize the renal waste products and use them as nutrients for growth. As the microbes grow and replicate, they create colonies capable of utilizing even more nitrogenous waste products, which are then eliminated as solid waste. The Kibow Biotics technology is based upon the use of the bowel to support the function of the kidney.

A multi-site, 6-month, double-blind, placebo-controlled, cross-over human clinical trial is already complete with positive and promising data in Canada. Similar clinical trials will be completed soon in USA, Mexico, Argentina and Nigeria. Institutional Review Board (IRB) approval has been obtained for dose escalation studies to be carried out at the Mayo Clinic in Rochester, Minnesota.

Priced economically, Kibow Biotics is conveniently available through the company website: http://www.kibow.com.

The development of Kibow Biotics has been made possible through partial federal funding obtained in the form of two National Institutes of Health (NIH) fast-track SBIR grants from the National Institute of Diabetes, Digestive and Kidney Disease (NIDDK). Additional support has been provided by USAID.

For more information, visit http://www.kibow.com.

Forward-looking statements

This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Kibow Biotics(R), for kidney health in USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Kibow Biotics will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Kibow Biotics may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Kibow Biotics. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, risks associated with completing clinical trials of product candidates, the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Web site: http://www.kibow.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

CONTACT: Natarajan Ranganathan, Ph.D., Interim CEO and Senior VP (R&D), of
Kibow Biotech, Inc., +1-610-353-5130

Web site: http://www.kibow.com/


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES